- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04830813
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Clinical Study of Chiauranib Capsule in Patients With Progressed or Relapsed Small-cell Lung Cancer After 2 Lines Chemotherapy (CHIS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRa and c-Kit), mitosis-related kinase Aurora B and chronic inflammationrelated kinase CSF-1R in a high potency manner with the IC50 at a single-digit nanomolar range. In particular, Chiauranib showed very high selectivity in the kinase inhibition profile with little activity on off-target non-receptor kinases, proteins, GPCR and ion channels, indicative of a better drug safety profile in terms of clinical relevance.
In July 2017, the sponsor initiated a phase Ib/II trial (CAR105). As of October 9, 2020, a total of 42 subjects entered the safety analysis and 41 subjects entered the efficacy analysis. The results of the phased trial analysis show the preliminary efficacy of this product in the treatment of SCLC at ≥3 lines.
This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with relapsed or refractory small cell lung cancer, in the meantime, exploreing the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Yuankai Shi
- Phone Number: 8610-87788495
- Email: syuankaipumc@126.com
Study Contact Backup
- Name: Yu Chen
- Phone Number: 8610-56102349
- Email: chenyu@chipscreen.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Recruiting
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Yuankai Shi, MD
- Phone Number: +86-10-8778-8293
- Email: syuankai@cicams.ac.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, age ≥ 18 years and ≤75 years;
- Cytologically or histologically confirmed small cell lung cancer;
- Patients have received at least 2 different systemic chemotherapy regimens (contained platinum based regimen) , and progressed or relapsed
- At least one measurable lesion that can be accurately assessed ( RECIST1.1 criteria). If the only site of measurable disease is in a previously irradiated area, the patient must have documented progression of disease in this area.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Laboratory criteria are as follows:
- Complete blood count: absolute neutrophil count (ANC) ≥1.5×10^9/L ; platelets ≥75×10^9/L; hemoglobin (Hb) ≥80g/L ;
- Biochemistry test: total bilirubin≤1.5×ULN; alanine aminotransferase (ALT) , aspartate aminotransferase(AST)≤2.5×ULN(ALT,AST≦5×ULN if liver involved); serum creatinine(cr)≤1.5×ULN;
- Coagulation test: International Normalized Ratio (INR) < 1.5.
- Life expectancy of at least 3 months.
- All patients must have given signed, informed consent prior to registration on study.
Exclusion Criteria:
- Patients who known to brain metastases with neurological symptoms;
- Screening period imaging shows that the tumor has invaded the periphery of important blood vessels or the investigator judges that the tumor is likely to invade important blood vessels and cause hemorrhage during the trial
- Pleural fluid, ascites, pericardial effusion with clinical symptoms or need to be drained during the screening period
- Patients with second primary cancer, except: adequately treated basal cell or squamous cell skin cancer, curatively treated in-situ cancer of the cervix, unless received curative treatment and with documented evidence of no recurrence during the past five years
- Patients who have been used aurora kinase inhibitors, or VEGF/VEGFR inhibitors
- Patients have used any anti-cancer therapy, including adiotherapy, chemotherapy, immunotherapy, target therapy, and other anti-tumor treatments within 28 days before the first dose
- Patients have used experimental drugs or devices within 28 days before the first dose
- Patients received major surgical operations within 28 days before the first dose, or patients with serious non-healing wounds, ulcer or fracture at the time of screening
- With the exception of alopecia, any ongoing toxicities (>CTCAE grade 1) caused by previous cancer therapy
Patients with uncontrolled or significant cardiovascular disease, including:
- Grade II or higher Congestive heart failure, unstable angina pectoris, myocardial infarction (NYHA Classification) within 6 months prior to study entry; or arrhythmia requiring treatment, or Left Ventricular Ejection Fraction (LVEF) < 50% during screening stage.
- Primary cardiomyopathy (dilated cardiomyopathy, hypertrophic cardiomyocyte, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, et,al).
- History of significant QT interval prolongation, or Corrected QT Interval QTc≥450ms(male),QTc≥470ms(female)at screening.
- patient's treatment record of using at least 2 antihypertensive drugs at the same Within 14 days before the first dose, or uncontrolled hypertension (> 140/90 mmHg) during the screening period.
- Obstructive atelectasis that requires chest radiotherapy or surgery during the screening period or CT or MRI of the chest during the screening period shows interstitial lung disease or pulmonary fibrosis or lung inflammation that requires treatment, or within 6 months before the first dose history of pneumonia requiring oral or intravenous steroid treatment
- Patients with factors that could affect oral medication (such as dysphagia,chronic diarrhea, intestinal obstruction, After small bowel resection,etc), or undergone gastrectomy, or history of gastrointestinal perforation
- Proteinuria positive(≥1g/24h)
- Active bleeding within 2 months before the first dose, or anticoagulant drugs are being taken during the screening period, or the investigator judges that there is a high risk of bleeding during the screening period
- History of deep vein thrombosis or pulmonary embolism within 6 months before the first dose
- Active infections that require systemic treatment (oral, intravenous infusion) during the screening period
- Screening for HIV antibody positive
- Screening test for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive with virus replication, hepatitis C antibody (HCV-Ab) positive with virus replication
- Any mental or cognitive disorder, that would impair the ability to understand the informed consent document, or the compliance of study
- Candidates with drug and alcohol abuse
- Women of childbearing potential not willing to use and utilize an adequate method of contraception (such as intrauterine device, contraceptive and condom) throughout treatment and for at least 12 weeks after the last dose; pregnant or breastfeeding women; the result of urine pregnancy test was positive at screening; Man participants not willing to use and utilize an adequate method of contraception throughout treatment.
- Any other condition which is inappropriate for the study according to investigators' judgment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chiauranib
Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
|
Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
Other Names:
|
Placebo Comparator: Placebo
Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
|
Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: From date of the first dose of study drug until the date of first documented progression or relapse or date of death from any cause, whichever came first, assessed up to 24 months
|
Progression-free survival
|
From date of the first dose of study drug until the date of first documented progression or relapse or date of death from any cause, whichever came first, assessed up to 24 months
|
OS
Time Frame: From date of the first dose of study drug until the date of death from any cause, assessed up to 24 months
|
Overall survival
|
From date of the first dose of study drug until the date of death from any cause, assessed up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: Up to a minimum 24 weeks after the last participant's first dose, or progression, or 75% subjects died
|
Objective reponse rate
|
Up to a minimum 24 weeks after the last participant's first dose, or progression, or 75% subjects died
|
DOR
Time Frame: from the date of first documented objective response until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
Duration of response
|
from the date of first documented objective response until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
DCR
Time Frame: Up to a minimum 24 weeks after the last participant's first dose, or progression, or 75% subjects died
|
Disease-control rate
|
Up to a minimum 24 weeks after the last participant's first dose, or progression, or 75% subjects died
|
percentage of AEs
Time Frame: 28 days after the last participant 's last medication or new anti-tumor therapy
|
Safety
|
28 days after the last participant 's last medication or new anti-tumor therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yuankai Shi, Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Chiauranib
Other Study ID Numbers
- CAR302
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Cancer
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedTobacco Use Disorder | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB...United States
-
Washington University School of MedicineMerck Sharp & Dohme LLCWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small Cell Lung Extensive Stage
-
Shanghai Chest HospitalRecruitingSmall Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer, Combined TypeChina
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
Clinical Trials on Chiauranib
-
AkesoChipscreen Biosciences, Ltd.RecruitingSCLC,Extensive StageAustralia, China
-
Chipscreen Biosciences, Ltd.Terminated
-
Chipscreen Biosciences, Ltd.RecruitingOvarian Cancer | Relapsed or Refractory | Chiauranib | PaclitaxelChina
-
Chipscreen Biosciences, Ltd.Completed
-
Chipscreen Biosciences, Ltd.Recruiting
-
Chipscreen Biosciences, Ltd.Recruiting
-
Chipscreen Biosciences, Ltd.Completed
-
Chipscreen Biosciences, Ltd.CompletedSmall Cell Lung CancerChina
-
Chipscreen Biosciences, Ltd.H & J CRO International, Inc.Completed
-
Chipscreen Biosciences, Ltd.RecruitingSmall Cell Lung Cancer | Advanced Solid Malignant TumorUnited States